New Tokyo-based company Asajes Ventures is aiming to create a new financial risk-sharing product development model for companies, mostly from the West, looking to bring their late pipeline or commerci
With a shrinking Big Pharma market for discovery, in-licensing of compromised products, such as Medicines' Angiomax, represents a lower-risk, and at leat moderate-reward, strategy. by Roger Longman In